A new antihistamine, metalazine, is compared to placebo for…
A new antihistamine, metalazine, is compared to placebo for mild-to-moderate seasonal allergies. An allergy symptom visual analog scale of 0, meaning no symptoms, to 10, meaning the worst symptoms imaginable is used as the primary outcome. Metalazine was found to decrease the allergy symptoms visual analog scale by 3.2 points (95%CI -0.4 to 7.8). Which of the following statements best describes the potential type of statistical error present in this study?